1DHHS.Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents.April 07,2005.
2Wang C,Vlahov D,Galai N,et al.Mortality in HIV-seropositive versus seronegative persons in the era of highly active antiretroviral therapy:implications for when to initiate therapy.J Infect Dis,2004,190(6):1046-1054.
3Reisler RB,Han C,Birman WJ,et al.Grade 4 events are as important as AIDS events in the era of HAART.J Acquir Immune Defic Syndr,2003,34(4):379-386.
4Yeni PG,Hammer SM,Hirsch MS,et al.Treatment for adult HIV infection:2004 recommendations of the International AIDS Society-USA Panel.JAMA,2004,292(2):251-265.
5King MS,Bernstein BM,Walmsley SL,et al.Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir,but not lopinavir/ritonavir,in antiretroviral therapy-naive patients.J Infect Dis,2004,190(2):280-284.
6Loutify M,Baril J,Conway B,et al.Randomized controlled trial of once daily (QD) tenofovir (TDF),3TC and lopinavir/ritonavir (LPV/r) versus remaining on the same regimen in HIV-infected patients virologically suppressed on their first PI-containing HAART regimen.Program and abstracts of the 14th Annual Canadian Conference on HIV/AIDS Research,Vancouver,2005.
8Tossonian H,Grebely J,et al.Virologic efficacy and lipid profiles of atazanavir (ATV)-based regimens with or without ritonavir boosting in treatnent-experienced patients.Program and abstracts of the 14th Annual Canadian Conference on HIV/AIDS Research,Vancouver,2005.
9Hicks C,da Silva B,Benson C,et al.Extensive resistance testing during 5 years of lopinavir/ritonavir treatment in antiretroviral-naive HIV infected patients:Results from study M97-720.Program and abstracts of the XV International AIDS Conference,Bangkok,2004.
10NoorMA,ParkerRA,O'MaraE,et al.The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.AIDS,2004,18(16):2137-2144.
